The unmatched chemo-,
regio-, and stereoselectivity of
enzymes
renders them powerful catalysts in the synthesis of chiral active
pharmaceutical ingredients (APIs). Inspired by the discovery route
toward the LPA1-antagonist BMS-986278, access to the API
building block (1S,3R)-3-hydroxycyclohexanecarbonitrile
was envisaged using an ene reductase (ER) and alcohol dehydrogenase
(ADH) to set both stereocenters. Starting from the commercially available
cyclohexene-1-nitrile, a C–H oxyfunctionalization step was
required to introduce the ketone functional group, yet several chemical
allylic oxidation strategies proved unsuccessful. Enzymatic strategies
for allylic oxidation are underdeveloped, with few examples on selected
substrates with cytochrome P450s and unspecific peroxygenases (UPOs).
In this case, UPOs were found to catalyze the desired allylic oxidation
with high chemo- and regioselectivity, at substrate loadings of up
to 200 mM, without the addition of organic cosolvents, thus enabling
the subsequent ER and ADH steps in a three-step one-pot cascade. UPOs
even displayed unreported enantioselective oxyfunctionalization and
overoxidation of the substituted cyclohexene. After screening of enzyme
panels, the final product was obtained at titers of 85% with 97% ee and 99% de, with a substrate loading
of 50 mM, the ER being the limiting step. This synthetic approach
provides the first example of a three-step, one-pot UPO-ER-ADH cascade
and highlights the potential for UPOs to catalyze diverse enantioselective
allylic hydroxylations and oxidations that are otherwise difficult
to achieve.